The cancer treatment developer floated in the middle of its range following $175m in venture funding from investors including Novo.
Checkmate Pharmaceuticals, a US-based cancer immunotherapy developer backed by pharmaceutical firm Novo, has floated in a $75m initial public offering on the Nasdaq Global Market.
The company priced 5 million shares at $15.00 each, at the middle of a $14 to $16 range. It floated on Friday and its shares closed at $13.06 at the end of yesterday, giving it a market capitalisation of about $280m.
Founded in 2015, Checkmate is working on therapeutics intended to treat cancer by harnessing…
